ReviewJournal of neurochemistry2016
Therapy and clinical trials in frontotemporal dementia: past, present, and future.
Review in Journal of neurochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 5 syntheses or guidelines pooled it, 137 citations in OpenAlex.
- Behavioral Treatment for Speech and Language in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech: A Systematic Review.Neuropsychology review · 2024Pooled it
- Research trends and hotspots for frontotemporal dementia from 2000 to 2022: a bibliometric analysis.Frontiers in neurology · 2024Pooled it
- Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Pooled it
- TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis.BMC neurology · 2018Pooled it
- Updated meta-analysis of the role of APOE ε2/ε3/ε4 alleles in frontotemporal lobar degeneration.Oncotarget · 2017Pooled it
- Efficacy of Communication Bridge-2 for primary progressive aphasia: A randomized controlled trial of communication intervention.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials.Brain : a journal of neurology · 2019Trial
- Review
- Morphometric features enhance phenotype discrimination in frontotemporal lobar degeneration.Brain communications · 2026Article
- Targeting Granulin Haploinsufficiency in Frontotemporal Dementia: From Genetic Mechanisms to Therapeutics.International journal of molecular sciences · 2025Review
- Impact of dementia on outcomes in older patients with COVID-19: A nationwide inpatient sample analysis.Australasian journal on ageing · 2025Article
- Enhancing early detection of cognitive impairment in primary care with the TabCAT-BHA.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- GABAergic modulation of beta power enhances motor adaptation in frontotemporal lobar degeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Benzoxazole-derivatives enhance progranulin expression and reverse the aberrant lysosomal proteome caused by GRN haploinsufficiency.Nature communications · 2024Article
- Differential diagnosis of frontotemporal dementia subtypes with explainable deep learning on structural MRI.Frontiers in neuroscience · 2024Article
- Advances in the Diagnosis and Management of Psychotic Symptoms in Neurodegenerative Diseases: A Narrative Review.Journal of geriatric psychiatry and neurology · 2023Review
- Post-Diagnostic Support for Behaviour Changes in Young-Onset Dementia in Australia.Brain sciences · 2023Article
- Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Dorsomedial prefrontal hypoexcitability underlies lost empathy in frontotemporal dementia.Neuron · 2023Article
- Harnessing the potential of machine learning and artificial intelligence for dementia research.Brain informatics · 2023Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Frontotemporal dementia (FTD) is a common form of dementia with heterogeneous clinical presentations and distinct clinical syndromes. This article will review currently available therapies for FTD, its related disorders and their clinical evidence. It will also discuss recent advancements in FTD pathophysiology, treatment development, biomarker advancement and their relation to recently completed or currently ongoing clinical trials as well as future implications. Frontotemporal dementia (FTD) is a type of dementia with distinct clinical syndromes. Current treatments involve off-label use of medications for symptomatic management and cannot modify disease course. Advancements in FTD pathophysiology, genetics, and biomarkers have led to development of small molecules targeting the underlying pathology in hopes of achieving a disease-modifying effect. This article will review current therapies for FTD, discuss advancements in FTD pathophysiology, therapy development, biomarker advancement, their relation to recent clinical trials and future implications. This article is part of the Frontotemporal Dementia special issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.